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The main role of the human immune system is to eliminate cells presenting foreign
antigens and abnormal patterns, while maintaining self-tolerance. However, when facing
highly variable pathogens or antigens very similar to self-antigens, this system can
fail in completely eliminating the anomalies, leading to the establishment of chronic
pathologies. Prototypical examples of immune system defeat are cancer and Human
Immunodeficiency Virus-1 (HIV-1) infection. In both conditions, the immune system is
persistently exposed to antigens leading to systemic inflammation, lack of generation of
long-term memory and exhaustion of effector cells. This triggers a negative feedback
loop where effector cells are unable to resolve the pathology and cannot be replaced
due to the lack of a pool of undifferentiated, self-renewing memory T cells. In addition,
in an attempt to reduce tissue damage due to chronic inflammation, antigen presenting
cells and myeloid components of the immune system activate systemic regulatory and
tolerogenic programs. Beside these homologies shared between cancer and HIV-1
infection, the immune system can be shaped differently depending on the type and
distribution of the eliciting antigens with ultimate consequences at the phenotypic
and functional level of immune exhaustion. T cell differentiation, functionality, cytotoxic
potential and proliferation reserve, immune-cell polarization, upregulation of negative
regulators (immune checkpoint molecules) are indeed directly linked to the quantitative
and qualitative differences in priming and recalling conditions. Better understanding of
distinct mechanisms and functional consequences underlying disease-specific immune
cell dysfunction will contribute to further improve and personalize immunotherapy. In
the present review, we describe relevant players of immune cell exhaustion in cancer
and HIV-1 infection, and enumerate the best-defined hallmarks of T cell dysfunction.
Moreover, we highlight shared and divergent aspects of T cell exhaustion and T cell
activation to the best of current knowledge.
Keywords: HIV infection, cancer, lymphocytes, cellular immunity, exhaustion, senescence, anergy, immune
checkpoint
INTRODUCTION
The primary function of the human immune system is to protect the host by reacting upon the
encounter of foreign antigens, as well as to prevent autoimmunity through self-recognition. Two
arms orchestrate the activation of the immune system: the innate response triggered within the
first hours and the adaptive response mounted over the following days, able to recognize and target
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specific antigens and to generate memory. T cells are the major
component of the adaptive immune system consisting of CD4
and CD8T cells (1), being the latter key players in the physical
elimination of tumor and virus-infected cells.
Most naïve T cells encounter their targets, presented by
professional antigen presenting cells (i.e., dendritic cells, DCs),
in secondary lymphoid organs (2). Such priming is crucial for
determining the acquisition of functional attributes by T cells
(3, 4). DCs govern the nature of primed T cells via the provision
of processed antigens in the form of peptide/MHC complexes
(signal I) and other important signals, including costimulatory
interactions (signal II) and inflammatory cytokines (signal III)
(5). Once activated, T cells undergo massive clonal expansion,
differentiate into potent effectors, and express chemokines
and homing receptors necessary for migration into peripheral
tissues. Effector CD4T cells produce several cytokines depending
on the polarization determined by the cognate antigen and
the extracellular milieu, effector CD8T cells express cytotoxic
molecules, such as perforin and granzymes, and produce effector
cytokines. The production of cytotoxic molecules and cytokines
is needed to help contain the spread of pathogens and tumors.
The fate of naïve CD8T cell differentiation is also determined
by interdependent variables such as frequency of contact with
the immunological synapses, epitope antigenicity, T cell receptor
(TCR) affinity for cognate targets and the presence of CD4T cell
help (6). After CD8T cell expansion and antigen elimination,
any further immune activation is prevented by the upregulation
and engagement of co-inhibitory molecules such as Cytotoxic
T Lymphocyte Antigen-4 (CTLA-4) and Programmed Death-
1 (PD-1). Most effector T cells die by apoptosis (contraction
phase), but about 5–10% survive and differentiate into memory
T cells. Different theories for memory T cell development have
been suggested (7), but recent findings strongly suggest that long-
lived memory CD8T cells would arise from a subset of effector
T cells through a process of dedifferentiation (8). Memory T
cells are then maintained in the absence of antigens (homeostatic
expansion) and can exert rapid effector functions in response to
previously encountered antigens (1, 9).
Any disturbance of conventional activation signals may
drive T lymphocytes to alternative cell fates, i.e., anergy,
tolerance and exhaustion. This plasticity has evolved to
constrain autoimmunity and excessive immune responses
that would otherwise cause undesired tissue damage and
immune-pathological conditions. Whereas, anergy is established
during priming, due to the absence of costimulatory signals,
and senescence is defined as growth arrest after extensive
proliferation, exhausted T cells arise from cells which initially
gained effector functions but became gradually dysfunctional
due to continuous TCR stimulation by persistent antigens
(10). Overlapping and discriminating functional and molecular
features of these alternative cellular conditions have been
comprehensively investigated (11, 12). In the present review, we
describe the establishment and hallmarks of T cell exhaustion
in HIV-1 infection and cancer. In addition, we highlight the
parameters that allow the discrimination between functionally
distinct T cell states, which are exhausted, activated, and memory
T cells.
EMERGENCE OF T CELL EXHAUSTION
T cell exhaustion was initially described in the mouse model
of LCMV infection (13–16), where, initially functional (17)
and then transcriptional analyses led to the identification of
PD-1 as first and main molecule associated with this status
(15, 18, 19). Afterwards, high PD-1 levels have been observed
in Simian Immunodeficiency Virus (SIV) infected Rhesus
Macaques (15, 20–22) as well as in HIV-1 infected patients
(23–25) and this was related to T cell impaired function and
disease progression. In HIV-1 infection, T cell exhaustion is
caused by antigen persistency and impaired CD4T cell help
(26, 27). During the acute phase of the infection, CD8T cell
responses are generated, but they are incapable of mediating
complete virus clearance. HIV-1 is, indeed, endowed with a
high mutation rate capacity that leads to a quick and efficient
escape from immune cells (28, 29). Moreover, lymphoid follicles
have been shown to be enriched in HIV-1/SIV-infected CD4
cells, and poorly infiltrated by CD8T cells during early SIV
infection. Consistently, the frequency of SIV-specific CD8T cells
entering the lymphoid follicles is inversely associated with the
levels of infected cells, suggesting a new mechanism of viral
persistency (30). While infected cells are not eradicated, T
cells are continuously exposed to viral antigens, leading to a
permanent expression of negative receptors and consequently to
T cell dysfunction (15, 31–34). Of note, beside antigen escape,
HIV-1 preferentially infects HIV-1-specific CD4T cells (35),
leading to profound consequences in the immune-pathogenesis
of the disease (28). HIV-1-specific CD4T cells expand at high
frequency during the early phase of the infection. Later on,
their number decreases in blood and secondary lymphoid
organs (36), due to killing by HIV-1-specific CD8T cells, virus
cytopathic effects and pyroptosis triggered by abortive viral
infection (37). In an early stage, CD8T cell responses are
also quickly impaired (27, 38–40), nevertheless this loss of
function is partially restored in the presence of HIV-1 specific
CD4T cells (13, 27), highlighting the importance of CD4T cell
depletion in determining CD8T cell exhaustion. CD4T cells
indeed provide help for CD8T cells by producing supportive
cytokines including interleukin (IL)-2 and IL-21, which can
act directly on the responding CD8T cells (41–48). IL-2 has
a pivotal importance during priming of CD8T cell response,
in order to generate functional memory cells able to perform
homeostatic turnover and to mount potent secondary responses
(49). IL-21 instead has a major role in sustaining and expanding
memory CD8T cells (43, 44). In mice, CD4T cell help has been
recapitulated by CD27 agonism that enhanced specific CD8T
cell effector functions in response to vaccination or a viral
infection (50).
Induction of T cell exhaustion is a common trait between
HIV-1 infection and cancer (17), however key differences
distinguish antiviral from anti-tumor immunity due to the
pathogenesis of the two diseases (Figure 1 and Table 1). The
immunogenicity of the tumor is shaped by the immune system
through a process called “immunoediting,” as the pivotal
work of Bob Schreiber first showed 15 years ago (116). In
a first phase, the adaptive and the innate immune systems
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FIGURE 1 | CD8T cell exhaustion in HIV-1 and cancer. T cell exhaustion in HIV-1 infection and cancer presents common origins and hallmarks, but also different
features. The shared cause of T cell exhaustion is antigen persistency due to immune escape mechanisms. Moreover, in HIV-1 infection, the high viral mutational rate
contributes to the immune escape while the preferential tropism of the virus for HIV-1 specific CD4T cells leads to CD4T cell loss that is also a main contributor of
CD8T cell exhaustion. In cancer, immunoediting and TME immunosuppression are peculiar determinants of tumor-specific CD8T cell exhaustion. In both cancer and
HIV-1 infection TOX has been identified as a master regulator of the transcriptional and epigenetic reprogramming of exhausted T cells. In HIV-1, T-betdim/Eomeshigh
subset defines highly exhausted CD8T cells, however in CD8T cells from cancer patients T-bet and Eomes are expressed in T cells with different levels of exhaustion.
At the protein level, the co-expression of many ICs has been identified as hallmark of T cell exhaustion in both cancer and HIV-1 infection. Exhausted cells are also
characterized by functional and survival defects including reduced effector functions, expansion capacity and increased susceptibility to apoptosis. Metabolic rewiring
is also a key player of T cell exhaustion, however in HIV-1-infected patients little/no information is available so far.
synergize to recognize and eliminate malignant cells using
conventional mechanisms (elimination phase). These include:
the specific recognition of tumor-associated antigens and the
expression of effector molecules by T lymphocytes (type I
and II- interferon, perforin, Fas/FasL, tumor necrosis factor
(TNF)-related apoptosis-inducing ligand—TRAIL), analogously
to a viral infection, paralleled by the expression of recognition
molecules such as NKG2D or ligands on tumor cells (induced
by DNA damage and stress pathways) (117). Early infiltration of
tumors by immune cells such as pro-inflammatory macrophages,
both CD4 and CD8T lymphocytes, NK, and DCs is crucial for
tumor control (118–121). In the second phase, dormant tumor
cells survive in equilibrium with the immune system where
immunosuppressive and anti-tumor functions are balanced
(equilibrium phase). In this phase, the tumor microenvironment
(TME) is composed of several cell types that produce variable
amounts of immune-suppressing and immune-stimulating
molecules. In addition, tumors show a low proliferation
rate and progressively undergo editing, resulting in tumor
cell variants able to escape immune control (escape phase)
(122). Clinically detectable tumors belong to this last and
most studied phase with cancer cells proliferating with no
or limited constraints. Tumor cells directly induce T cell
exhaustion through the acquisition of somatic mutations, which
confer increased immune resistance and survival, altogether
contributing to prolonged antigen exposure. Ultimately, the
exhaustion state is the outcome of a transcriptional and
metabolic reprogramming induced by immunosuppressive
cytokines (i.e., TGF-β, IL-10) and metabolites (i.e., lactate,
kynurenine, adenosine, PGE2) produced by cancer cells (121,
123) and tumor infiltrating immunosuppressive cell subsets,
including regulatory T cells, myeloid-derived suppressor cells,
tumor-associated macrophages, cancer-associated fibroblasts,
adipocytes, and endothelial cells (124). Moreover, anti-tumor
T cells compete with cancer and immunosuppressive cells for
nutrient availability and immunostimulatory factors. Current
Frontiers in Immunology | www.frontiersin.org 3 June 2020 | Volume 11 | Article 1350
Vigano et al. Patterns of Chronic Antigen Exposure
TABLE 1 | Hallmarks of exhaustion.
IC expression
HIV-1/chronic infection Cancer
PD-1 (23–25) PD-1 (51–56)
CTLA-4 (57) CTLA-4 (53)
TIM-3 (34, 58–60) TIM-3 (52, 53)
LAG-3 (61) LAG-3 (53)
TIGIT (62, 63) TIGIT (64–66)
CD160 (33, 67, 68) CD160 (69)
2B4 (CD244) (67, 68) 2B4 (CD244) (70)
BTLA (60) BTLA (71)






Transcription factors expressed by exhausted CD8T cells
HIV-1/chronic infection Cancer
Master regulators: TOX, TCF-1 (82–85)
EOMES 187 (85) STAT3 (86, 87)
BLIMP-1 (88–91) BLIMP1 (55, 92)
TOX (93) TOX (64, 93)
NOTCH (94) NR4A2 (95)
NFATc1 (96) NFAT (95)
BATF (97–100) BATF (55)
IRF4 (100) IRF4 (85)
VHL (101) VHL (101)
FOXO1 (102) FOXO1(102)
PBX3 (19) FOXP1 (103)





PD-1 locus demethylation was observed in models of chronic infections (106) and in
HIV-1 infected patients (107)
Tumor-reactive makers CD39 and CD103 are demethylated in tumor-reactive CD8T
cells (whole-genome methylation profiling) (108)
Increased accessibility to Pdcd, Havcr2, and Batf loci and to loci encoding genes
involved in negative regulation of T cell effector functions (109)
Recurrence after anti-PD-1 therapy was associated with the hypermethylation of the
PD-L1 promoter (110)
Recent studies show the stability of the PD-1 locus demethylation even after PD-1
blockade (111)
Two chromatin states have been identified in exhausted T cells: (i) plastic and
reversible, (ii) fixed dysfunctional state resistant to reprogramming (112)
Identification of exhaustion-specific enhancer that contains essential RAR, T-bet, and
Sox3 motifs (109)
HDAC6-selective inhibitors directed peripheral and infiltrating T cells toward a
Th1/effector phenotype (113)
Exhausted T cells acquire heritable de novo methylation programs able to restrict T cell expansion and clonal diversity during PD-1 blockade treatment. A
DNA-demethylating agent (Decitabine) improved T cell responses and tumor control during PD-1/PD-L1 blockade (114)
9–12 exhaustion clusters have been identified from epigenomic-guided mass cytometry profiling data (115)
data suggest that nutrient deprivation is inducing, per se, T cell
dysfunction (125–127).
CD8T cell responses are quickly impaired during both early
viral infection and tumor establishment.
Recently, terminally exhausted CD8T cells have been
characterized and distinguished from their progenitors
depending upon the expression of PD-1, TIM-3, CD44, Eomes,
T-bet, TCF-1, Slamf6, and CXCR5 (51, 67, 128–134). Exhausted
T cell progenitors were characterized in LCMVmodels as pool of
cells expressing TCF-1+/PD-1int/CXCR5+/Slamf6+, responding
to PD-1 blockade and differentiating into terminally exhausted
CD8T cells (TCF-1−/PD-1high/TIM-3+) (128–131). Their
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presence was also described among circulating tumor-reactive
CD8T cells in melanoma patients and within TILs in primary
melanomas (135) and non-small-cell lung cancer (NSCLC)
(132). Interestingly, recent studies have better characterized
a subset of CD8+/CXCR5+ T cells with proliferative capacity
and able to infiltrate B cell follicles and inflamed tissues in
the presence of chronic antigen exposure and inflammation
(129, 131, 136–143). This subset shows heterogeneous phenotype
and gene expression profile depending on the pathogenic
context, still it is distinct from the CXCR5− counterpart pool and
maintain cytotoxic properties (144). In addition of being part of
the TCF-1+/PD-1int progenitor pool (129, 145), these cells have
been described as having variable levels of exhaustion and being
similar to Tfh cells (20, 108, 129, 131, 141, 146–149). This is
reflected in their capacity to help in the control of viral infection
and of tumor growth, in the promotion of inflammation and
in the induction of B cell responses (108, 136, 137, 144). The
formation and maintenance of the TCF-1+/PD-1int progenitor
pool is orchestrated by the thymocyte selection-associated high
mobility group box protein TOX. While TOX is a key player
in the establishment of the exhausted state, its role is largely
dispensable for the generation of effector and memory T cells.
Antigen persistency is likely to be the cause of Tox induction
since its expression is dependent on calcineurin and NFAT2.
TOX is therefore the translator of persistent stimulation into
a distinct T cell transcriptional and epigenetic developmental
program leading to T cell exhaustion. TOX is also important for
the subsequent differentiation into terminally exhausted cells
that is counteracted and regulated by the phosphatase PTPN2
(82–84, 150–152). PTPN2 abrogation increases the number
of terminally differentiated cytotoxic CD8T cells promoting
effective immune response, tumor/viral clearance and improved
response to inhibitory molecules blockade (84). TOX induces
genes that are important for the exhaustion precursor formation,
including transcription factors (TFs) (e.g., Tcf7, Nr4a2, and Tox
itself) and co-inhibitory receptors (e.g., Pdcd1, Lag3, CD244,
and Havcr2). In conclusion, persistent activation and induction
of TOX are common drivers of T cell exhaustion in both viral
infection and tumor pathogenesis. However, specific players
such as CD4T cell loss and TME heterogeneity in infection and
cancer, respectively, contribute to define distinct and overlapping
traits of exhausted T cells in the two conditions.
HALLMARKS OF T CELL EXHAUSTION IN
HIV-1 INFECTION
Many studies have indicated HIV-1-induced T cell exhaustion
as main hallmark of the disease. Of note, HIV-1-specific CD8T
cells selectively show features of exhaustion as compared to
bulk CD8T cell populations and unrelated virus-specific T cells
circulating in the same subject, as described in human and animal
studies (153–155).
Expression of Multiple ICs
A complex network of stimulatory and inhibitory surface
molecules orchestrates the functionality of CD8T cells (156, 157).
A cardinal feature of exhausted T cells in HIV-1 infection is the
sustained expression of multiple inhibitory immune checkpoints
(ICs) (Table 1).
The first and, to date, the most important IC involved in
CD8T cell exhaustion in chronic infections (15, 23–25, 52, 158)
is PD-1. During chronic stimulation, PD-1 expression on virus-
specific CD8T cells is high and sustained (23–25, 68) because
of mechanisms involving both TFs [i.e., T-bet (159), Blimp-1
(88, 160)] and soluble factors [i.e., IFN-α (161) and RANTES
(156)]. In turn, PD-1 signaling affects the function, proliferation,
survival and chemotaxis of CD8T cells (23–25, 156, 162). In vivo,
PD-1high SIV-specific CD8T cells are characterized by a higher
turnover (163).
The interaction of PD-1 with its two ligands PD-L1 and
PD-L2 on hematopoietic and non-hematopoietic cells triggers
the phosphorylation of two cytoplasmic domains and the
subsequent recruitment of cytosolic tyrosine phosphatases
Shp2 and Shp1, the TCR-phosphorylating kinase Lck, and
the inhibitory tyrosine kinase Csk (164, 165). These effectors
mainly act by antagonizing the CD28 costimulatory signaling
(166–168) and the TCR signaling via dephosphorylation of
SLP76 and ZAP70 (164, 166). Moreover, signaling molecules
including ERK, Vav, PLCγ, PI3K, and Ras have been described
as downstream targets of PD-1 signaling in T cells, leading to
an impairment in metabolism, survival and cell growth (10,
165, 168, 169). PD-1 is also expressed by CXCR5+ CD8T cells
(20, 170), a population particularly interesting for therapeutic
purposes.
In addition, landmark studies in LCMV (67) and then
SIV/HIV-1 infection (33, 34, 62, 171, 172) highlighted the
relevance of multiple ICs co-expression (i.e., CD160, 2B4, TIM-
3, T cell immunoreceptor with Ig and ITIM domains-TIGIT,
CTLA-4 and LAG-3) to define deeply exhausted virus-specific
CD8T cells. The co-expression of multiple ICs may be due to
their transcriptional co-regulation and non-redundant roles in
the physiological control of CD8T cell responses (130, 173–
176). Increased disease progression, viral replication and lower
CD4T cell counts were directly associated with PD-1 (23),
CTLA-4 (171), TIM-3 (58, 59), LAG-3 (61), and TIGIT (62,
63) expression. In addition, the superior proliferative capacity
and the maintenance of cytotoxic functions by CXCR5+ CD8T
cells concur with a lower surface expression of ICs and a
higher expression of co-stimulatory receptors (CD28 and ICOS)
as opposed to the CXCR5− counterpart (129, 131, 148). Of
importance, SIV and HIV-1 specific CD8T cell proliferation
in vitro improves when distinct ICs (i.e. CD160, 2B4, TIGIT,
BTLA, TIM-3) are blocked (24, 33, 60, 62) and administration
of anti-PD-1 in SIV infected macaques (177–181) and HIV-
1-infected patients (182) increases T cell immune responses,
however clinical efficacy remains controversial (181, 183–
190).
More recently, in SIV-infected macaques, the expression of
CD6 by PD-1+ CD8T cells was associated with a reduced
proliferation, cytokine secretion and cytotoxic capacity when
compared to their CD6− counterpart. The frequency of
CD6+PD-1+ CD8T cells positively correlated with SIV viral load
and combined targeting of CD6 and PD-1 effectively restored the
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CD8T cell proliferation capacity in vitro, suggesting that CD6
may be a new immunotherapeutic target (72).
Recently, the combination of transcriptomic and proteomic
data allowed the identification of multiple cell clusters that
were evolving with HIV-1 disease progression or initiation
of ART (64). These data may lead to the understanding of
new specific features of disease evolution and drive novel
therapeutic approaches.
Alteration in TFs Expression and
Epigenetic Regulation
Genomic approaches were recently applied to investigate the
transcriptional profile of virus-specific exhausted CD8T cells,
revealing their unique molecular signature as compared to non-
exhausted cells (Table 1) (19, 109, 111, 112, 115). Transcriptional
analyses showed that exhaustion results from centrally connected
pathways (19, 115, 191), having TOX as a master regulator.
Indeed, TOX expression correlates with the presence of an
exhausted phenotype during chronic infections in mice (LCMV)
and humans (HCV) (82). In addition to TOX, several TFs
coordinate gene expression networks, including PBX3, EOMES,
BLIMP1 (Prdm1) (88–91), NOTCH (94), NFATc1 (96), basic
leucine zipper transcription factor, ATF-like (BATF) (97–99),
IRF-4, von Hippel–Lindau disease tumor suppressor (VHL),
FOXO1, and FOXP1 (99–102, 130, 159, 192–198). At the
molecular level, TCR stimulation leads to the induction of
Tox expression (83) and induces the recruitment of TFs, like
Notch (94), NFATc-1 (96), IRF-4 and BATF (100), at the
promoter of different inhibitory receptors, ultimately driving
their upregulation. Among the genes induced by TOX, Tcf7
(encoding TCF-1) promotes the generation of exhaustion
precursors through the induction of Eomes and c-Myb in early
chronic infection, whereas PD-1 is needed to stabilize this pool
(85, 199). IRF4 was also shown to favor CD8T cell exhaustion
while limiting memory T cell differentiation (100). Importantly,
PD-1high/Eomeshigh and PD-1low/T-bethigh T cells are both
necessary to contain chronic LCMV infection (130). However,
CD8T cells presenting a T-betdim/Eomeshigh profile represent a
highly exhausted state with elevated levels of multiple inhibitory
receptors (i.e., PD-1, CD160, and 2B4) (200, 201). In turn, PD-
1 signaling reduces the expression of Bcl-xl (168), favoring the
apoptosis of activated T cells (162, 202), and induces BATF
leading to a decreased cytokine production, cytotoxic potential
and proliferation rate of virus-specific CD8T cells (97, 99). BATF
induces the expression of T-bet and BLIMP-1 and correlates with
PD-1 expression in murine models of chronic viral infection.
BLIMP-1 is upregulated in patients with progressive, as opposed
to non-progressive, HIV-1 infection (194, 203, 204) and is also
associated with reduced T cell proliferation and effector-cytokine
secretion capacity; however, these functions are restored by
knocking down BATF or BLIMP-1 (88, 99). BLIMP-1 can also be
induced in T cells upon priming with HIV-1 pulsed DCs together
with other inhibitory molecules, including PD-1, TIM-3, LAG-3,
and CTLA-4 (205).
The characterization of the epigenetic landscape of exhausted
T cells gives novel and key insights to decipher the function
of TFs. Comprehensive whole-genome analysis of chromatin
accessibility (ATAC-seq) (206), has shown that exhausted CD8T
cells have a distinct epigenetic signature (95, 109, 111, 112, 207,
208). For instance, exhausted CD8T cells have several chromatin
regions with reduced accessibility (e.g., the Ifng, Ccr7, Il7r, Nt5e,
Tcf7, and Lef1 loci), while presenting open chromatin regions
in loci that govern the expression of IC molecules (e.g., Pdcd1,
Tigit, Ctla4), of ectoenzymes implicated in metabolic regulation
(e.g., Cd38, Entpd1), of chemokines and cytokines (e.g., Xcl1)
and of TFs (e.g., Eomes, Ikzf2, Tox) (64, 109, 111). The deletion
of chromatin accessible regions including TF binding motif for
RAR-retinoic acid receptor, T-bet, and Sox3 cause a dramatic
reduction in PD-1 expression, demonstrating their important
role in shaping exhausted T cell transcriptional profiling (64, 109,
208). Moreover, during chronic LCMV infection, the Pdcd1 locus
become completely demethylated (106), while the histone H3 is
less diacetylated in CD8T cells, indicating a loss in epigenetically
active genes (209). In parallel, the transcriptional regulatory
region of the PD-1 promoter is unmethylated in PD-1hi HIV-1-
specific CD8T cells but not in donor-matched naive cells (PD-
1−) (107). Thus, in chronic LCMV (106) and HIV-1 infection
(107), PD-1 expression in virus-specific CD8T cells is controlled
by the chromatin accessibility of the gene itself (epigenetic
control) and by TF governing its expression (Figure 2).
Loss of Functions
Exhaustion in chronic viral infections has been described in both
mice and humans as the progressive decrease in the capacity of
virus-specific CD8T cells to secrete cytokines, proliferate and
exert cytotoxicity (23, 68, 210–213) as a consequence of persisting
virus and antigen load (214). Loss of function characterizing
exhaustion is hierarchical: IL-2 production is one of the first
function to be extinguished, followed by TNF-α production,
whereas the ability to produce interferon-γ (IFN-γ) is more
resistant to inactivation (155, 213, 215–218).
Consistently with the hierarchical loss of effector functions
by exhausted T cells, Riley et al. (219) demonstrated that such
effector functions depend on the strength of PD-1 signaling, thus
on PD-1 expression levels.
HALLMARKS OF T CELL EXHAUSTION IN
CANCER
The identification of exhausted T cells in the cancer setting
was inspired by previous knowledge gained in chronic viral
infections. In human melanoma metastasis, T cells sharing
many features of the exhaustion signature identified in LCMV
infection were found (53). However, as discussed above, the
establishment of exhaustion occurs differently in viral infection
and cancer, the latter involving a complex network of players
and mediators. The repertoire of tumor-specific T lymphocytes
is generally devoid of highly avid autoreactive cells due to
central and peripheral tolerance mechanisms, and priming may
be inefficient due to the lack of co-stimulation, an inflammatory
milieu and/or the presence of immunoregulatory cellular subsets
(220). Therefore, a more heterogeneous pool of cells, fully
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FIGURE 2 | Epigenetic imprinting of T cell exhaustion. Shortly after antigen exposure, naïve T cells generate effector T cells that are armed to eliminate foreigner
antigens. Activated T cells demethlyate loci dedicated to the expression of effector functions and activation genes. Activated genes include also ICs (i.e., PD-1)
needed for starting the contraction phase once the antigen is cleared. After the contraction phase, memory T cells survive and present a specific transcriptional profile,
while PD-1 expression is reduced. If the antigen persists, memory T cells cannot be generated and effector functions are progressively lost. In addition, some genes of
the demethylated loci remain transcriptionally active sustaining the expression of ICs and leading to T cell functional exhaustion. In the context of a therapeutic
intervention or physiological immune control of chronic antigen exposure (i.e., ART, Anti-PD-1, Elite controllers), exhausted T cells can restore, at least partially, their
effector functions and reduce the expression of ICs such as PD-1. However, implicated loci remain demethylated, potentially causing a rapid restoration of the
exhausted state after treatment interruption and the failure of the immune system to completely eradicate the antigens.
activated or not, may undergo the dysfunctional program.
Consistently with their virus-specific counterparts, these cells
are characterized by increased expression of ICs (19, 64,
221), impaired homeostatic response to cytokines (222) and
altered epigenetic and transcriptional programs (10, 191, 223).
In contrast to HIV-1 infection where little/no information is
available to date, the rewiring of the T cell metabolism in
cancer immunopathogenesis is a well-characterized hallmark of
exhaustion (224, 225). Of note, PD-L1 engaged by PD-1 acts
as an anti-apoptotic molecule and increases chemoresistance
on cancer cells through phosphorylation and activation of the
PI3K/AKT pathway, as opposed to inactivation in T cells (226–
228). Notwithstanding the recent burst of investigations on T cell
exhaustion in cancer, studies in human remain challenging and
animal models should be tuned to better reflect the slow course
of natural cancer progression and its antigenic contexts (high/low
mutational load).
Expression of Multiple ICs
In line with what is described for HIV-1 infection, a high
and sustained expression of ICs is consensually considered as
the main hallmark of T cell exhaustion in the cancer setting
(Table 1). Tumor-specific CD8 TILs express high levels of PD-
1 associated to impaired function (54). PD-1 is expressed
upon TCR engagement and NFAT nuclear translocation (96)
and may drive exhaustion of T cells undergoing persistent
antigen exposure (18, 229). Exhausted T cells can co-express
PD-1 together with different ICs, including, LAG-3, CTLA-
4, BTLA, TIGIT, 2B4 (CD244), VISTA, KLRG1 (53, 73, 230)
and TIM-3 (52, 131, 199). Inhibitory receptors signal through
non-overlapping pathways and use different mechanisms to
regulate T cell function ultimately inducing exhaustion: they
sequester target receptors and ligands involved in activation
pathways (ectodomain competition), they dampen the signals
from activating receptors and they mediate transcription of
inhibitory genes (10). Importantly, the hierarchical co-expression
of multiple inhibitory receptors has been associated with a more
severe grade of cellular dysfunction (231). Additional, recently
identified markers of CD8T cell exhaustion in cancer include:
CD39 (77, 78), LAYN, whose expression is mutually exclusive
with LAG-3 in hepatocellular carcinoma patients (80), and
CXCL13 (53, 79). Moreover, Stanczak et al. (81) described the
Sia-SAMP:Siglec-9 as an inhibitory pathway in NSCLC, where
high frequencies of Siglec9+CD8+ TILs inversely correlate with
survival (81). Finally, CD160+ CD8T cells have been shown
to express higher PD-1 levels than the CD160− counterpart, to
have less proliferative and cytotoxic potential and to be enriched
among CD8 TILs in pancreatic cancer patients (69). Recently, a
CXCR5+ CD8T cell population has been observed to expand in
diffuse large B cell lymphoma (232), follicular lymphoma (144)
and HBV-related hepatocellular carcinoma (137, 139, 141, 149).
Circulating, tumor infiltrating, and lymphoid CXCR5+ CD8T
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cells were shown to co-express PD-1 and, in contrast with chronic
viral infection (129, 131, 134, 148), TIM-3 (134, 140), however
they were functionally less exhausted than the CXCR5− CD8T
cell population and expressed genes related to stem-like plasticity
and cytotoxicity (140, 141, 149). The frequency of this subset was
correlated with a better prognosis in follicular lymphoma (144),
pancreatic (139), colorectal (137, 141), and lung (140) cancer,
suggesting its anti-tumor activity. However, combined blockade
of TIM-3, PD-1 or IL-10R pathways could increase the cytotoxic
activity of CXCR5+ CD8T cells indicating their limited lytic
potential (139, 149).
Alteration in TFs Expression and
Epigenetic Regulation
Tumor cells, together with immune and non-immune
populations of the TME, contribute to a well-defined gene
expression profile of dysfunctional anti-tumor T cells (Table 1),
partially overlapping with that of exhausted T cells in chronic
infections, by releasing molecules and establishing inhibitory
contacts. In addition, recent studies in murine and human cancer
suggest that TILs display a broad spectrum of dysfunctional states
shaped by the multifaceted suppressive signals that occur within
the TME (64, 130, 135). Several signaling pathways through the
TCR, suppressive cytokines (TGF-ß, IL-6), inhibitory receptors,
metabolites (adenosine, prostaglandins, lactate), enzymes (e.g.,
nitric oxide synthase, reactive oxygen species, indoleamine-2,3
dioxygenase), low pH, hypoxia and nutrient deprivation, lead
to the final transactivation of TFs controlling the expression of
different gene sets (101, 104, 173, 233, 234). As described for
chronic infections, a complex pattern of TFs drives the initial
triggering of differentiation toward the exhausted phenotype,
including TOX, NFAT, Blimp-1, BATF, FoxO1, VHL, IRF4
(93, 234), Bcl-6, cMAF, and STAT3 (86, 87, 104, 235, 236).
These factors exert distinct roles in T cells at different stages
of differentiation and they do not exclusively govern gene
expression in exhausted T cells. The epigenomes of different
T cell subsets contribute to the context-specific functions of
shared TFs. For instance, STAT3 dependent transcriptional
regulation limits both TILs recruitment and cytotoxic function
by downregulating IFN-γ, CXCR3, and CXCL10 expression
and inducing ROR-γt (87, 236). Of note, EOMES and T-bet
are expressed during the whole course of tumor progression
and, in contrast to chronic viral infections, they do not help in
distinguishing an exhausted-progenitor subset from terminally
differentiated exhausted T cells (Figure 1) (10, 55). More
recently, new technological advances (i.e., mass cytometry
and single cell sequencing) are allowing a deeper examination
of the molecular properties of dysfunctional T cells at the
single cell level. These studies represent milestones for the
comprehension of T cell biology in the context of complex
TME, dominated by a high heterogeneity of cellular subsets.
Recently, Bengsch et al. (64, 115) identified 9 distinct T cell
clusters among exhausted CD8T cells in HIV-1 infection and
human lung cancer by using transcriptomic- and epigenetic-
guided mass cytometry. This study also assigned an exhaustion
score to each of the subsets based on functional features
(64, 115), those providing relevant insight for the design of IC
blockade therapies.
Loss of Functions
As in chronic viral infections, exhausted T cells found in
different tumor types have reduced effector functions as shown
in terms of cytokine production and cytotoxicity (53, 237).
Nevertheless, the hierarchy by which T cells progressively lose
their functions is less clear (53, 54, 231, 237–239). TILs are
not functionally inert and, to some extent, contribute to tumor
control (231, 240). The efficacy of IC inhibitors and IL-2-driven
ex vivo expansion of functional TILs is an indirect proof of
this impaired yet present anti-tumor activity. Furthermore, TILs
can be highly heterogeneous among distinct cancer types as
evidenced by their different capacity to respond to IC blockade.
For instance, in small-cell lung cancer patients, subsets of PD-
1high TILs are enriched in tumor-specific T cells and their
presence is a predictor of clinical response to anti-PD-1 therapy
(132, 241–243). On the contrary, T cells infiltrating breast tumor
retain robust cytokine production and degranulation capacity
(244) notwithstanding the expression of PD-1. In breast cancer
patients, PD-1 expression is therefore less predictive of TILs
dysfunction and this may explain the modest clinical responses
to anti-PD-1 or anti-PDL therapies.
The proliferative potential of exhausted T cells is considered
limited due to unresponsiveness to homeostatic cytokines such
as IL-7, IL-15 and IL-21 (211, 245, 246). However, the previously
mentioned TCF-1+/ PD-1int progenitor pool of exhausted
T cells has a residual proliferative potential that allows the
replenishment of the pool of exhausted antigen-specific CD8T
cells by expanding and differentiating into the numerically
larger population of TCF-1−/PD-1hi/TIM-3+ terminal progeny,
characterized by a higher co-expression of other ICs and limited
proliferative capacity (135, 199).
In a work by Li H. and co-workers, the intra-tumoral
immune infiltrates of 25 melanoma patients differing for
staging and treatments were analyzed by scRNA-seq for a
deep characterization of dysfunctional T cells both in terms
of transcriptional states and TCR clonality (238). Exhausted T
cells expressing previously reported ICs (i.e., PD-1 and LAG-
3) were observed in many patients. Importantly, intra-tumoral
CD8T cells could cluster in two distinct subpools. T cells
belonging to the first pool spanned a wide range of transcriptional
states, from transitioning to highly dysfunctional, expressed a
gradient of inhibitory molecules and were specifically observed
in tumor tissue. Some of the expressed regulatory molecules
(CSF1, ZBED2) were also shared with regulatory T cells. A second
subpool included T cells with cytotoxic potential, but limited
proliferative capacity. This second pool of T cells could represent
bystander T cells, likely from the circulation. Tumor-specific T
cells were enriched in the exhausted pool, as previously observed
for NSCLC (132). Strikingly, T cells with an initial buildup of
the dysfunctional programmaintained a clear proliferative signal
with a doubling time of few days and rapid turnover. This
dynamic and active T cell state fits previously suggested models
of establishment of exhaustion at the tumor site (238). Common
mechanisms of the emergence of exhaustion are present among
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tumor types, but differences in the relative abundance of the
subsets can be due to different TME, i.e., availability of antigens
and exposure to inhibitory factors as well-shown for TILs in
breast cancer (244). This is then reflected in the different capacity
to respond to IC blokade that is not only heterogeneous among
tumor types but also among individuals (244), as reviewed
elsewhere (247).
In conclusion, in both HIV-1 infection and established
tumors, T cell exhaustion is likely driven by TOX and the
subsequent coordinated expression of several TFs. Exhausted
T cells are characterized by loss of effector functions, high
expression of multiple ICs, reduced homeostatic expansion,
altered TFs expression, and remodeled chromatin. However,
while in HIV-1 infection T-bet and EOMES allow the distinction
between progenitors and fully exhausted T cells, in cancer
patients TCF-1 and STAT3 may instead be the key TFs. The
avidity and the hierarchy of the loss of function of exhausted
T cells in cancer patients is less well-described than in chronic
infections. Exhausted cells present in the TME may be highly
heterogeneous and not include only the antigen-specific ones;
new insights will explain how these aspects could affect the
response to IC blockade.
EXHAUSTED VS. ACTIVATED/MEMORY
CD8T CELLS
Given the high heterogeneity and dynamicity of the memory
CD8T cell compartment (64, 238, 248), novel immunotherapies,
aiming at rescuing the functionality of exhausted T cells, would
require the ability to selectively distinguish exhausted from
memory and activated effector T cells.
Expression of Surface Molecules
The solely qualitative evaluation of ICs expression by CD8T
cells, per se, does not discriminate between exhausted and
activated T cells. As previously mentioned, inhibitory receptors
that are transiently expressed on activated effector T cells show
a higher and sustained upregulation on exhausted T cells,
triggered by a persistent antigen stimulation. For instance,
PD-1 is rapidly upregulated upon T cell activation (249)
and persists at moderate levels in healthy subjects with a
preferential expression on effector memory T cells (162, 250–
253). During chronic infections, PD-1 expression on viral-
specific T cells increases (23, 38, 128, 254, 255) and does not
always reverse upon antigen removal (175, 256). HIV-1-infected
patients responding to ART show reduced expression levels
of PD-1 on virus-specific CD8T cells after antigen clearance
(257), still these levels are maintained above the physiological
threshold observed in healthy individuals. This may be due to
a broad systemic immune activation, to the effects of common
gamma-delta chain cytokines sustaining PD-1 expression on bulk
CD8T cells (258, 259) or to the irreversible transcriptional and
epigenetic alteration affecting highly exhausted T cells (106, 260)
(Figure 2).
As previously mentioned, the degree of exhaustion is directly
associated with the pattern of co-expression of different co-
inhibitory receptors (67). First, this is mechanistically relevant,
as simultaneous blocking of multiple ICs results in a synergistic
reversal of T cell exhaustion in both cancer and chronic
infections (171, 239, 261–263). Second, the identification of
co-expression subsets may lead to a better discrimination
between exhausted and activated T cells, reducing the risk for
off-targets effects.
Many studies have shown that chronic antigen stimulation
of T cells drives an IC expression pattern. For instance, TIM-3
and PD-1 cooperate for the induction of CD8T cell exhaustion
in cancer (52, 264–266) and chronic viral infections (34). In
LCMV infection, PD-1 and TIM-3 identify a population of T
cells strongly enriched in gene signatures of terminal exhaustion
and harboring reduced proliferative capacity, longevity and
cytokine production (64). In HIV-1 infected patients, ART
significantly suppresses TIM-3 expression on HIV-1 specific
CD8T cells (267) indicating that, like PD-1, it is dependent
on chronic TCR stimulation. Moreover, the expression profile
of CD56 and TIM-3 can discriminate between individuals that
naturally control HIV-1 replication (elite patients) and ART-
treated patients (268). After virus-clearance and CD4T cell
recovery, patients receiving ART show a quantitative loss of
CD56+ CD8T cells coupled to an exhausted phenotype, as shown
by TIM-3 upregulation. Elite patients maintain a pool of cytolytic
CD56+ CD8T cells comparable to healthy individuals. Similarly,
CD160 expression also allows the distinction between exhausted
and activated (PD-1+) HIV-1 specific CD8T cells (33). Indeed,
only cells co-expressing CD160 and PD-1 (PD-1highCD160high)
are functionally impaired in HIV-1 infected patients (33).
In cancer, the activation of ICs other than PD-1/PD-L1
and CTLA-4 can be induced by adaptive resistance to IC
therapies. The treatment of such tumors could benefit from the
combination of anti-PD-1 with different immune checkpoint
molecules (e.g., LAG-3, TIM-3, TIGIT), activation markers
and cytokines/chemokines (269). On the other hand, T cell
dysfunction is characterized by decreased levels of co-stimulatory
molecules, of their ligands and of adaptor molecules impairing
the co-stimulatory signaling. Among these, CD44, LY6C, killer
cell lectin-like receptor subfamily G member 1 (KLRG1), CD122
(IL-2Rβ), and CD127 (IL-7R), tumor necrosis factor receptor
(TNFR)- associated factor 1 (TRAF1), CD28, and 41BBL have
been described (67, 175, 246, 258, 259). In particular, exhausted
T cells display the same profile of effector T cells with reduced
telomere length and low levels of CD62L, CD127, and CD122
expression (1, 40, 153, 215, 258, 270–273). Their incapacity to
respond to IL-7 and IL-15 (88, 128, 159, 245) lead to the lack
of homeostatic expansion in the absence of antigens (1, 88, 128,
130, 159) and, ultimately, to death (14, 154, 215, 256, 274–276).
T cell dysfunction is also characterized by the downregulation of
the signaling adaptor TNFR-associated factor 1 (TRAF1) both in
HIV-1 infected patients with progressive disease and in LCMV
chronically-infected mice (259). In HIV-1 infected patients,
TRAF1 expression negatively correlates with PD-1 expression
and viral load and knockdown of TRAF1 in CD8T cells from
viral controllers results in decreased HIV-1 suppression ex
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vivo. TGF-β is responsible for the post-translational loss of
TRAF1, while IL-7 signaling is able to restore TRAF1 levels.
Transfer of TRAF1+ memory T cells or a combination treatment
with IL-7 and agonist anti-4-1BB antibody in chronic LCMV
infection improve T cell expansion and viral control in a
TRAF1-dependent manner (259). Patient samples of renal cell
carcinoma also show reduced expression of TRAF1 compared
with normal kidney. This confers resistance to apoptosis and
higher proliferative capacity to renal cancer cells (277). These
findings identify TRAF1 as a potential biomarker of T cell
dysfunction and therapeutic target. Moreover, combining PD-
1 blockade with an agonistic antibody to 4-1BB dramatically
improved T cell function and LCMV control in vivo (278).
Still, the role of positive co-stimulatory molecules in rescuing
exhausted T cells remains poorly described.
Transcriptional and Epigenetic Regulation
Another key difference between exhausted and activated T cells
resides in the TFs (18, 19, 191, 279). Both the quality of
the expressed TFs and the genes they can target, distinguish
exhausted T cells from activated and memory CD8T cells (191,
280, 281).
Transcriptional profiling analysis demonstrated that CD8T
cell memory and exhaustion reflect distinct states defined by
coordinated sets of modules. Specific genes and pathways
differentially implicated in exhaustion vs. memory include genes
involved in epigenetics, DNA damage, and WNT signaling, such
as Rtp4, Foxp1, Ikzf2, Zeb2, Lass6, Tox, and Eomes (191). The
study by Bengsch et al. (64, 115) associates effector and exhausted
T cells to a higher expression of CD39, LAG-3, TCF-1, Helios,
CTLA-4 and PD-1, Eomes, TOX, 2B4, TIGIT, respectively.
During acute infection, T-bet and EOMES play pivotal roles in
the generation of terminally-differentiated (2, 282) and central-
memory (283–285) CD8T cells respectively, while CD8 effector
T cells co-express T-bet and EOMES (286). In contrast, during
chronic infection, exhausted T cell subsets express either T-
bet or EOMES in a somehow mutually exclusive pattern and
they identify pools of non-terminal progenitor and terminally-
differentiated exhausted CD8T cells, respectively (Figure 1)
(130). Of note, anti-PDL1 therapy only improves the function
of the T-bethi subset, while having little impact on EOMEShi
cells (128, 130), indicating an important aspect of population
dynamics in IC blockade-mediated reversal of T cell exhaustion.
A similar population of CD8T cells responding to IC blockade,
(PD1int/TCF-1+), has been recently described as precursors
of terminally exhausted cells (PD1high/TCF-1−/TIM-3+) to be
distinguished from memory precursors cells (PD1−/TCF-1+) on
the basis of several epigenetic and transcriptional alterations such
as higher expression of CXCR5 and Slamf6 (199).
By using a combined experimental and computational
approach, Singer et al. (105) described mutually exclusive gene
modules to distinguish dysfunctional from activated T cells in a
murine colon carcinoma model. In particular, metallothionins,
responsible for regulating the intracellular zinc metabolism,
and zinc-dependent TFs were found to be highly enriched in
dysfunctional CD8 TILs. GATA-3, a zinc-finger TF, consistently
emerged as a driver of T cell dysfunction. Moreover, the
expression of the co-inhibitory receptors PD-1 and TIM-3 was
maintained upon metallothion-deletion, being uncoupled from
the gene dysfunctional module (105).
Epigenetic studies also helped in identifying patterns
distinguishing T cell exhaustion from T cell activation/memory
profile. Recent epigenetic studies in mice and humans indicate
that exhausted T cells represent a unique T cell lineage, compared
to effector and memory T cells and are a stable, distinct and
disease-relevant cell type (109, 111, 112).
HIV-1- and HCV-specific CD8T cell genomes present a
high accessibility to exhaustion-associated nucleotide regions.
On the opposite, the genome of CMV-specific CD8T cells
is characterized by a higher accessibility to memory-specific
nucleotide regions (109). Interestingly, the accessibility to
exhaustion-specific regions is reduced in CD8T cells specific
for HCV epitopes that undergo viral escape (109), indicating
that chronic exposure is needed to shape exhaustion-associated
epigenetic imprinting.
Studies focusing on Pdcd1 locus revealed that during the
effector phase of an acute LCMV infection, the promoter
regions were largely demethylated to become remethylated as
the infection solved and CD8T cell memory formed (106, 287).
In the context of a chronic LCMV infection, the demethylation
observed in the Pdcd1 locus during chronic LCMV infection
was instead stable and no remethylation was observed, even
when viral titers and PD-1 protein expression by exhausted
CD8T cells decreased (106) or after transfer in recipient mice
(260). Along the same lines, the unmethylated state of the Pdcd1
locus did not change in T cells from subjects with a viral load
controlled by ART for several years or from elite controllers
(107). This suggests that the epigenetic program of the PD-
1 locus is stabilized after prolonged exposure to HIV-1 virus
despite different levels of PD-1 surface expression. Consistently,
the transcriptome and the epigenome of terminally exhausted
CD8T cells (PD-1high/TCF-1−/TIM-3+) are stably rewired and
resistant to remodeling after PD-1 blockade (111, 114) (Figure 2).
These data strongly suggest that epigenetic remodelingmay be
required to further improve strength and breadth of the efficacy
of immune checkpoint blockade.
In conclusion, exhausted T cells can be distinguished from
activated T cells by the higher and sustained co-expression of
IC molecules, as well as by a phenotype skewed toward effector
memory cells with reduced co-stimulatory molecules expression.
Moreover, the systemically induced immune activation and
the stable transcriptional and epigenetic imprinting established
during T cell exhaustion do not allow the restoration of
IC molecules expression to the levels measured in healthy
donors even after antigen removal/reduction. Among the TFs
analyzed, T-bet, and EOMES allow the distinction between
activated and exhausted CD8T cells in HIV-1 infection,
while metallothionins and GATA-3 have been suggested as
discriminators in cancer patients.
CONCLUSIONS
Recent major advances in immunotherapy ultimately
demonstrated the potentiality of the immune system in disease
control. However, they also proved that existing strategies are
hampered by the immune tolerance established by IC expression
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on T cells. In addition, despite the significant difference in the
availability of clinical information concerning immunotherapy
efficacy in cancer and HIV-1 infection, there is still a long way
to go for the scientific community to decipher the mechanisms
of immunosuppression in different indications. Recently, new
technological advances (such as mass cytometry, single cell
sequencing, ATAseq, metabolomics) are allowing a deeper
examination of the molecular properties of dysfunctional T cells
at the single cell level. These studies represent milestones for
the comprehension of T cell biology in the context of complex
TME, dominated by a high heterogeneity of cellular subsets
and in HIV-1 infection where current immunotherapy may not
improve T cell responses (64, 115). These data may lead to the
understanding of new specific features of disease evolution and
drive novel immunotherapeutic approaches.
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